600085.SH
同仁堂
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 23.78
+0.04%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 16.6B | 17.3B | 18.6B | 17.9B | 15.4B |
| Cost of Revenue | 9.7B | 9.9B | 10.4B | 9.4B | 7.9B |
| Gross Profit | 6.9B | 7.4B | 8.2B | 8.4B | 7.5B |
| Operating Expenses | |||||
| R&D Expense | 307.2M | 292.0M | 269.4M | 279.8M | 217.4M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 1.4B | 1.4B | 1.5B | 1.5B | 1.3B |
| Selling & Marketing Expense | 3.3B | 3.5B | 3.6B | 3.4B | 3.1B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 5.1B | 5.3B | 5.5B | 5.3B | 4.8B |
| Cost and Expenses | 14.8B | 15.2B | 15.9B | 14.7B | 12.7B |
| Operating Income (EBIT) | 1.8B | 2.0B | 2.8B | 3.1B | 2.7B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 1.8B | 2.0B | 2.8B | 3.1B | 2.7B |
| Income Tax Expense | 369.9M | 393.5M | 525.0M | 497.4M | 512.9M |
| Bottom Line | |||||
| Net Income | 1.1B | 1.2B | 1.5B | 1.7B | 1.4B |
| Earnings from Cont. Ops | 1.4B | 1.6B | 2.3B | 2.6B | 2.2B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.1B | 1.2B | 1.5B | 1.7B | 1.4B |
| Per Share | |||||
| Basic EPS | CN¥0.79 | CN¥0.87 | CN¥1.11 | CN¥1.22 | CN¥1.04 |
| Diluted EPS | CN¥0.79 | — | — | — | — |
| Revenue Per Share | CN¥12.15 | CN¥12.58 | CN¥13.56 | CN¥13.03 | CN¥11.21 |
| Shares | |||||
| Basic Shares Outstanding | 1.4B | 1.4B | 1.4B | 1.4B | 1.4B |
| Diluted Shares Outstanding | 1.4B | 1.4B | 1.4B | 1.4B | 1.4B |
| Profitability Metrics | |||||
| EBITDA | — | 2.5B | 3.2B | 3.5B | 3.1B |
| D&A | — | 453.5M | 409.5M | 401.4M | 399.0M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026